GERMANTOWN, Md., Jan. 9, 2025
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a
biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of
patients, today announced Helen
Sabzevari, PhD, President and CEO of Precigen, will present
at the 43rd Annual J.P. Morgan Healthcare Conference on
Thursday, January 16, 2025 at
9:00 AM PT in San Francisco, California.
Participants may view details for this event through Precigen's
website in the Events & Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, regulatory approvals, commercial launches and related
milestones, the promise of the Company's portfolio of therapies,
and in particular its CAR-T and AdenoVerse therapies. Although
management believes that the plans and objectives reflected in or
suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and
actual future results may be materially different from the plans,
objectives and expectations expressed in this press release. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. For further information on
potential risks and uncertainties, and other important factors, any
of which could cause the Company's actual results to differ from
those contained in the forward-looking statements, see the section
entitled "Risk Factors" in the Company's most recent Annual Report
on Form 10-K and subsequent reports filed with the Securities and
Exchange Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302346389.html
SOURCE Precigen, Inc.
